Effect of home blood pressure monitoring for blood pressure control in hypertensive patients taking multiple antihypertensive medications including fimasartan (the FORTE study)

Table 1 Comparison of the Baseline Demographic and Confounding Characteristics Between the Groups

	Control (n = 1225)	Intervention (n = 1258)	P Values
Age (year)	58.85 (12.82)	57.26 (12.43)	*0.001* ^W
Sex (male/female)	724/501	666/592	*0.002* ^C
Body mass index (kg/m²)	25.39 (3.6)	25.74 (3.7)	*0.037*^W
Baseline SBP (mmHg)	161.2 (14.57)	159.1 (15.16)	*< 0.001* ^W
Baseline DBP (mmHg)	97.4 (11.4)	97.7 (11.8)	0.345 ^W
Antihypertensive medication (single/combination)	94/1131	203/1055	*< 0.001* ^C
Target organ damage^a	122 (10.0%)	228 (18.7%)	*< 0.001* ^C
Cardiovascular risk factor	1120 (91.4%)	1112 (88.4%)	*0.012*^C
Age (men ≥55 years, women ≥65 years)	641 (52.3%)	566 (45.0%)	*< 0.001* ^C
Male sex	724 (59.1%)	666 (52.9%)	*< 0.001* ^C
Smoking	249 (20.3%)	252 (20.0%)	0.855^C
Dyslipidemia^b	150 (12.2%)	220 (17.5%)	*< 0.001* ^C
FBS ≥100 mg/dL	149 (12.2%)	201 (16.0%)	*0.006*^C
BMI ≥25 kg/m²	574 (50.0%)	693 (55.1%)	0.133^C
Central obesity (men ≥90 cm, women ≥80 cm)	256 (20.9%)	326 (25.9%)	*0.003*^C
Family history (men < 55 years, women < 65 years)	60 (4.9%)	29 (2.3%)	*< 0.001* ^C

Data are presented as mean (standard deviation) or number (%)
SBP systolic blood pressure, DBP diastolic blood pressure, FBS fasting blood glucose, BMI body mass index, eGFR estimated glomerular filtration rate, LDL-C low-density lipoprotein cholesterol, HDL-C high-density lipoprotein cholesterol
C: chi-square test
W: Wilcoxon rank sum test
^aTarget organ damage was defined as a composite of 1) stroke, transient ischemic attack, or vascular dementia; 2) left ventricular hypertrophy, angina, myocardial infarction, or heart failure; 3) albuminuria (albumin level > 30 mg/g) or chronic kidney disease (eGFR < 60 mL/min/1.73 m²); 4) peripheral vascular disease (ankle-brachial index < 0.9), pulse wave velocity > 10 m/sec, intimal thickness of the carotid artery > 1.0 mm, or large artery disease; and 5) stage 3 or 4 hypertensive retinopathy
^bDyslipidemia was defined as total cholesterol level ≥ 230 mg/dL, LDL-C level ≥ 150 mg/dL, HDL-C level < 40 mg/dL, or triglyceride level ≥ 200 mg/dL

ISSN: 2056-5909